ABCG2 and triple-negative breast carcinoma: In the case of ABCG2, a recent study revealed that RNF180 increases the sensitivity of triple-negative breast cancer cells to gefitinib by degrading RAD51 and downregulation of efflux transporters, including ABCG2, ABCC1, and ABCB1 [70].